(Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.)
I have been following Soligenix (OTCQB:SNGX) since last summer and am still a big fan of the company. One of the reasons I like SGNX is that management can executes its strategy very well. In my previous articles about SNGX, I talked about its multiple clinical and preclinical programs targeting various indications including oral mucositis, Crohn's disease, and biodefense vaccines.
In this article, I am going to discuss a specific program, melioidosis, in which Soligenix is making progress.
Soligenix Initiates development of SGX943 for Melioidosis
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|